Deja Vu: EGF Receptors Drive Resistance to BRAF Inhibitors

Overview

Journal Cancer Discov

Specialty Oncology

Date 2013 May 10

PMID 23658295

Citations 13

Authors

Maria Romina Girotti

Richard Marais

Affiliations

Soon will be listed here.

Abstract

The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation.

Citing Articles

Nomogram based on autophagy related genes for predicting the survival in melanoma.

Deng G, Wang W, Li Y, Sun H, Chen X, Zeng F BMC Cancer. 2021; 21(1):1258.

PMID: 34809598 PMC: 8607622. DOI: 10.1186/s12885-021-08928-9.

Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Abd-Elrahman I, Nassar T, Khairi N, Perlman R, Benita S, Yehuda D Oncogene. 2020; 40(2):334-344.

PMID: 33128043 DOI: 10.1038/s41388-020-01529-z.

The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells.

Peppicelli S, Andreucci E, Ruzzolini J, Bianchini F, Nediani C, Supuran C J Enzyme Inhib Med Chem. 2020; 35(1):1185-1193.

PMID: 32396749 PMC: 7269050. DOI: 10.1080/14756366.2020.1764549.

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.

Laurenzana A, Margheri F, Biagioni A, Chilla A, Pimpinelli N, Ruzzolini J EBioMedicine. 2019; 39:194-206.

PMID: 30611716 PMC: 6355443. DOI: 10.1016/j.ebiom.2018.12.024.

Dabrafenib and its use in the treatment of metastatic melanoma.

Bowyer S, Lee R, Fusi A, Lorigan P Melanoma Manag. 2018; 2(3):199-208.

PMID: 30190849 PMC: 6094610. DOI: 10.2217/mmt.15.21.

References

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Held M, Langdon C, Platt J, Graham-Steed T, Liu Z, Chakraborty A . Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov. 2012; 3(1):52-67. PMC: 3546137. DOI: 10.1158/2159-8290.CD-12-0408. View

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387):100-3. DOI: 10.1038/nature10868. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Montero-Conde C, Ruiz-Llorente S, Dominguez J, Knauf J, Viale A, Sherman E . Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013; 3(5):520-33. PMC: 3651738. DOI: 10.1158/2159-8290.CD-12-0531. View

Corcoran R, Ebi H, Turke A, Coffee E, Nishino M, Cogdill A . EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3):227-35. PMC: 3308191. DOI: 10.1158/2159-8290.CD-11-0341. View

Falchook G, Lewis K, Infante J, Gordon M, Vogelzang N, Demarini D . Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13(8):782-9. PMC: 4109286. DOI: 10.1016/S1470-2045(12)70269-3. View

Hauschild A, Grob J, Demidov L, Jouary T, Gutzmer R, Millward M . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839):358-65. DOI: 10.1016/S0140-6736(12)60868-X. View

10.

R Girotti M, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D . Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2012; 3(2):158-67. PMC: 5321574. DOI: 10.1158/2159-8290.CD-12-0386. View

11.

Catalanotti F, Solit D, Pulitzer M, Berger M, Scott S, Iyriboz T . Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res. 2013; 19(8):2257-64. PMC: 3932005. DOI: 10.1158/1078-0432.CCR-12-3476. View

12.

Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-703. PMC: 3549295. DOI: 10.1056/NEJMoa1210093. View

13.

Hayes D, Lucas A, Tanvetyanon T, Krzyzanowska M, Chung C, Murphy B . Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012; 18(7):2056-65. PMC: 5157199. DOI: 10.1158/1078-0432.CCR-11-0563. View